← Patent-cliff monitor small molecule YORVIPATH PALOPEGTERIPARATIDE
Loss of exclusivity November 2042 latest FDA-listed patent expiry
Company ASCENDIS PHARMA BONE DISEASES AS
Drug detail Brand name YORVIPATH Active ingredient PALOPEGTERIPARATIDE Strength EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval August 2024 Marketing status RX
Listed patents Patent Expires Type 12403182 November 2042 product 12295989 September 2037 use U-3982 11857603 September 2037 use U-3982 11590207 September 2037 use U-3982 11918628 September 2037 substance, product 12453778 September 2037 use U-3982 11759504 September 2037 product 11890326 September 2037 substance, product 8906847 April 2031 substance, product
Regulatory exclusivity Code Expires ODE-492 August 2031 NCE August 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.